title: Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival.
authors.forename: B
authors.initials: B
authors.lastname: Taillan
authors.forename: G
authors.initials: G
authors.lastname: Garnier
authors.forename: S
authors.initials: S
authors.lastname: Schneider
authors.forename: A
authors.initials: A
authors.lastname: Pesce
authors.forename: J G
authors.initials: JG
authors.lastname: Fuzibet
authors.forename: P
authors.initials: P
authors.lastname: Dujardin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008727:Methotrexate